Tissue implants in treatment of parkinsonian syndromes in animals and implications for use of tissue implants in humans

Adv Neurol. 1993:60:707-14.

Authors

I J Kopin¹, K S Bankiewicz, R J Plunkett, D M Jacobowitz, E H Oldfield

Affiliation

¹ National Institute of Neurological Disorders, National Institutes of Health, Bethesda, Maryland 20892.

PMID: 8420215

No abstract available

Publication types

Review

MeSH terms

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Adrenal Medulla / transplantation
Animals
Basal Ganglia / physiopathology
Basal Ganglia / surgery
Brain Tissue Transplantation / physiology*
Dopamine / physiology
Fetal Tissue Transplantation / physiology
Haplorhini
Humans
Neurologic Examination
Oxidopamine
Parkinson Disease / physiopathology
Parkinson Disease / surgery*
Parkinson Disease, Secondary / chemically induced
Parkinson Disease, Secondary / physiopathology
Parkinson Disease, Secondary / surgery*
Rats
Receptors, Dopamine / drug effects
Receptors, Dopamine / physiology

Substances

Receptors, Dopamine
Oxidopamine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Dopamine